Want To Buy Crypto? Check Out The Top Movers For Today
Pulled from Benzinga Pro here's the list of the top crypto gainers and losers at the time of publication:
Tuesday’s Afternoon Update On Crypto Gainers and Losers
According to Benzinga Pro, the following are the crypto gainers and losers at the time of publication:
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
Guardant Health Inc (NASDAQ:GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ:NEO), Bloomberg reported citing people familiar with the…
Bloomberg Reported Sunday Guardant Health Decided Against Buying NeoGenomics
https://www.bloomberg.com/news/articles/2021-10-04/guardant-health-is-said-to-decide-against-neogenomics-takeover
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
Bloomberg reported that Guardant Health Inc (NASDAQ:GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ:NEO), citing people familiar with the matter. Related: Precision…
Neogenomics Shares Move Higher Amid Report Guardant Considering Takeover Of Co.
-Bloomberg
https://twitter.com/cfromhertz/status/1443924780328144896
Ten Cryptocurrency Data Points To Take Away from 2021
The new decade dawned to be very promising for the crypto sector, leading to increased adoption of cryptocurrencies and the development of new coins. The question of the survival of cryptocurrency has been enveloped by the enigma of their potential to benefit the financial division.
NeoGenomics’ Liquid Biopsy Subsidiary Inivata And Collaborators To Present Data That Further Validate The Application Of Its RaDaR(TM) MRD And InVisionFirst(R)-Lung Assays At The ESMO Congress 2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Morgan Stanley Maintains Overweight on NeoGenomics, Lowers Price Target to $58
Morgan Stanley maintains NeoGenomics (NASDAQ:NEO) with a Overweight and lowers the price target from $64 to $58.